- Home
- STLA vs IQV Comparison
STLA vs IQV Comparison
Compare STLA & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STLA
- IQV
- Stock Information
- Founded
- STLA 2021
- IQV 1982
- Country
- STLA Netherlands
- IQV United States
- Employees
- STLA N/A
- IQV N/A
- Industry
- STLA Auto Manufacturing
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- STLA Consumer Discretionary
- IQV Health Care
- Exchange
- STLA Nasdaq
- IQV Nasdaq
- Market Cap
- STLA 31.6B
- IQV 37.2B
- IPO Year
- STLA N/A
- IQV 2013
- Fundamental
- Price
- STLA $10.19
- IQV $213.93
- Analyst Decision
- STLA Buy
- IQV Buy
- Analyst Count
- STLA 4
- IQV 18
- Target Price
- STLA $12.65
- IQV $237.89
- AVG Volume (30 Days)
- STLA 18.4M
- IQV 1.7M
- Earning Date
- STLA 07-29-2025
- IQV 10-28-2025
- Dividend Yield
- STLA 5.65%
- IQV N/A
- EPS Growth
- STLA N/A
- IQV N/A
- EPS
- STLA N/A
- IQV 7.30
- Revenue
- STLA $171,605,402,237.00
- IQV $15,904,000,000.00
- Revenue This Year
- STLA N/A
- IQV $6.14
- Revenue Next Year
- STLA $5.22
- IQV $5.28
- P/E Ratio
- STLA N/A
- IQV $29.29
- Revenue Growth
- STLA N/A
- IQV 3.85
- 52 Week Low
- STLA $8.39
- IQV $134.65
- 52 Week High
- STLA $14.28
- IQV $225.91
- Technical
- Relative Strength Index (RSI)
- STLA 46.58
- IQV 59.18
- Support Level
- STLA $9.97
- IQV $209.46
- Resistance Level
- STLA $11.43
- IQV $222.59
- Average True Range (ATR)
- STLA 0.25
- IQV 6.00
- MACD
- STLA -0.09
- IQV -0.53
- Stochastic Oscillator
- STLA 18.63
- IQV 52.59
About STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.